13.99
Precedente Chiudi:
$12.85
Aprire:
$12.9
Volume 24 ore:
63,887
Relative Volume:
0.02
Capitalizzazione di mercato:
$14.57M
Reddito:
-
Utile/perdita netta:
$-1.13M
Rapporto P/E:
-0.2447
EPS:
-57.1626
Flusso di cassa netto:
$-2.63M
1 W Prestazione:
+12.55%
1M Prestazione:
+1.82%
6M Prestazione:
+130.86%
1 anno Prestazione:
-99.13%
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
PLRZ
Polyrizon Ltd
|
13.99 | 13.39M | 0 | -1.13M | -2.63M | -57.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Polyrizon Ltd Borsa (PLRZ) Ultime notizie
Polyrizon signs MOU to acquire 51% stake in Arrow Aviation By Investing.com - Investing.com South Africa
Will Polyrizon Ltd. stock hit new highs in YEARQuarterly Trade Report & Smart Money Movement Tracker - mfd.ru
Polyrizon stock rises on potential acquisition of Arrow Aviation By Investing.com - Investing.com South Africa
Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator - The Manila Times
Biotech Polyrizon lines up $5.8M deal for $19M private jet firm - Stock Titan
Polyrizon to develop intranasal formulation of Clearmind’s MEAI drug By Investing.com - Investing.com Nigeria
Clearmind partners with Polyrizon to develop intranasal MEAI formulation By Investing.com - Investing.com Nigeria
Polyrizon Ltd. (PLRZ) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Clearmind Medicine (CMND) Stock: Partners With Polyrizon to Advance Intranasal MEAI Therapy - parameter.io
Polyrizon climbs on Clearmind Deal - Baystreet.ca
Polyrizon to develop intranasal formulation of Clearmind’s MEAI drug - Investing.com
Clearmind Medicine stock surges after Polyrizon intranasal delivery deal By Investing.com - Investing.com Nigeria
Clearmind partners with Polyrizon to develop intranasal MEAI formulation - Investing.com
Clearmind Medicine stock surges after Polyrizon intranasal delivery deal - Investing.com
Polyrizon and Clearmind Partner on Intranasal Non-Hallucinogenic Neuroplastogen MEAI - TipRanks
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation - The Manila Times
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI - The Manila Times
Clearmind Medicine Inc. Partners with Polyrizon Ltd. to Develop Innovative Intranasal Formulation for MEAI in CNS Disorders - Quiver Quantitative
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic ... - Caledonian Record
Biotechs team up on intranasal, non-hallucinogenic addiction therapy - Stock Titan
Polyrizon shares gain on plan to buy majority stake in private aviation company - MSN
Polyrizon Signs MOU to Acquire 51% Stake in Arrow Aviation - Intellectia AI
Polyrizon Moves to Acquire 51% Stake in Global Private Aviation Firm Arrow Aviation - TipRanks
Polyrizon signs MOU to acquire 51% stake in Arrow Aviation - Investing.com
Polyrizon stock rises after announcing plan to acquire stake in private aviation firm - Investing.com Nigeria
Polyrizon stock rises after announcing plan to acquire stake in private aviation firm By Investing.com - Investing.com South Africa
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company - The Manila Times
Biotech firm Polyrizon eyes $19M private jet business - Stock Titan
Aug Setups: Is Polyrizon Ltd stock a value trapDay Trade & Real-Time Volume Spike Alerts - baoquankhu1.vn
Polyrizon stock rises on FDA submission for PL-16 viral blocker - Investing.com Nigeria
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Surprises Report: Can Polyrizon Ltd beat the S P 5002025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Sell Signal: Can Polyrizon Ltd disrupt its industry2025 Price Targets & Low Volatility Stock Recommendations - baoquankhu1.vn
Polyrizon begins usability study for intranasal allergy blocker By Investing.com - Investing.com Australia
Technical Analysis: Will Polyrizon Ltd outperform its industry peersJuly 2025 Earnings & Free Community Supported Trade Ideas - baoquankhu1.vn
Polyrizon Launches FDA-Aligned Usability Study for NASARIX Allergy Blocker - TipRanks
Polyrizon begins usability study for intranasal allergy blocker - Investing.com
Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker - The Manila Times
New nasal allergy blocker moves closer to human trials with FDA-guided study - Stock Titan
How rising interest rates impact Polyrizon Ltd. stockJuly 2025 Patterns & Expert Approved Momentum Ideas - bollywoodhelpline.com
Polyrizon’s PL-14 shows strong pre-clinical allergen-blocking advantage over standard nasal barrier - MSN
Polyrizon recives Nasdaq delisting notice - MSN
Polyrizon explores investments in defense, aviation and AI sectors By Investing.com - Investing.com Nigeria
Polyrizon Ltd to explore revenue-generating investment opportunities in high-growth sectors - marketscreener.com
Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet - manilatimes.net
Polyrizon Ltd To Explore Revenue-Generating Investment Opportunities In High-Growth Sectors - TradingView
User - FinancialContent
Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now - TechStock²
Polyrizon Ltd Azioni (PLRZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):